Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Clenil Modulite 100 micrograms inhaler (with Dose Indicator)

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Beclometasone dipropionate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Beclometasone dipropionate

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Clenil Modulite pressurised inhalation solution is used to help prevent the symptoms of mild, moderate or severe asthma. The active ingredient, beclometasone dipropionate, is one of a group of medicines called corticosteroids which are often referred to simply as steroids. Steroids have an anti-inflammatory action reducing the swelling and irritation in the walls of the small air passages in the lungs, and so ease breathing problems.

What you need to know before you take it

e Clenil Modulite Do not use Clenil Modulite:

  • if you are allergic to any of the ingredients of this medicine or to any other medicines used to treat asthma.
  • to treat a sudden attack of breathlessness. It will not help. Use a quick-acting 'reliever' inhaler for this purpose and carry it with you at all times. Warnings and precautions Talk to your doctor, pharmacist or nurse before using Clenil Modulite if any of the following applies to you:
  • you are being, or have ever been, treated for tuberculosis (TB).
  • you must avoid alcohol for any reason.
  • your asthma seems to be getting worse. Perhaps you are more wheezy and short of breath than usual, your 'reliever' inhaler seems to be less effective, you require more puffs from your 'reliever' inhaler than usual, or you do not seem to be getting better. Your doctor may need to increase the dose of your steroid inhaler or give you a course of steroid tablets, or change your treatment altogether. If you have an infection in your chest your doctor may prescribe a course of antibiotics.
  • when transferring from steroid tablets to an inhaler you find that, even if your chest is getting better, you feel generally unwell, you develop a rash, eczema or a runny nose and sneezing (rhinitis). Do not stop treatment with your inhaler unless your doctor tells you to. If you have been treated for a long time with high doses of inhaled steroid, you may require a course of steroid tablets or possibly a steroid injection in times of stress. For example, during admission to hospital after a serious accident, before an operation, during an acute attack of asthma or if you have a chest infection or other serious illness. Your doctor will decide if you need any extra steroid treatment and will also advise you as to how long you need to take the course of steroid tablets and how you should reduce these as you get better. If you are using Clenil Modulite instead of, or as well as taking steroid tablets, or if your doctor is trying to reduce the dose of your steroid tablets, you should carry a steroid warning card until your doctor tells you that you don't need to. Children and adolescents If your child is receiving prolonged treatment with Clenil, your doctor should regularly monitor their height to evaluate if growth impairment occurs. Other medicines and Clenil Modulite: Before starting treatment, please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Remember to take these medicines and your inhalers with you if you have to go into hospital. Some medicines may increase the effects of Clenil Modulite and your doctor may wish to monitor you carefully if you are taking these medicines (including some medicines for HIV: ritonavir, cobicistat). Pregnancy and breast-feeding: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Clenil Modulite contains alcohol: This medicine contains less than 9 mg of alcohol (ethanol) in each actuation, which at the maximum is equivalent to 0.88 mg/kg per dose in adults and 1.54 mg/kg per dose in children. The maximum amount of ethanol per dose in this medicine is equivalent to less than 2 ml of wine or beer. The small amount of alcohol in this medicine will not have any noticeable effects.

How to take it

Clenil Modulite Clenil Modulite is available in 4 different strengths. Your doctor will have decided which strength you need. Clenil Modulite 200 and Clenil Modulite 250 are not suitable for children. Always use your inhaler exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. Instructions for using your inhaler are given after the dosage section. It takes a few days for your inhaler to work. It is very important that you use it regularly. Do not stop treatment even if you feel better unless told to do so by your doctor. Do not stop using your inhaler abruptly. While you are using Clenil Modulite your doctor will want to check your asthma regularly by carrying out simple breathing tests and may need to carry out blood tests from time to time. Dosage: The starting dose will depend on how severe your asthma is and will be decided by your doctor. It may be higher than the doses given below. Your doctor will prescribe the lowest dose of Clenil Modulite that will control your symptoms. A device called a Volumatic spacer should always be used when:

  • adults, the elderly and adolescents 16 years of age and older are taking total daily doses of Clenil Modulite of 1,000 micrograms or more,
  • when Clenil Modulite is used in children and adolescents 15 years of age and under whatever dose has been prescribed. Clenil Modulite 50 micrograms The common starting dose is: Adults and the elderly: Children:

200 micrograms (4 puffs) twice a day 100 micrograms (2 puffs) twice a day

Usually the most you would take in a day is: Adults and the elderly: Children:

800 micrograms (16 puffs) 400 micrograms (8 puffs)

The total daily dose may be divided into 2, 3 or 4 doses per day. Clenil Modulite 100 micrograms The common starting dose is: Adults and the elderly: Children:

200 micrograms (2 puffs) twice a day 100 micrograms (one puff) twice a day

Usually the most you would take in a day is: Adults and the elderly: Children:

800 micrograms (8 puffs) 400 micrograms (4 puffs)

The total daily dose may be divided into 2, 3 or 4 doses per day. Clenil Modulite 200 micrograms The common starting dose is: Adults and the elderly only:

200 micrograms (1 puff) twice a day

Usually the most you would take in a day is:

800 micrograms (4 puffs)

The total daily dose may be divided into 2, 3 or 4 doses per day. This product strength is not suitable for children Clenil Modulite 250 micrograms The common starting dose is: Adults and the elderly only:

500 micrograms (2 puffs) twice a day

Usually the most you would take in a day is:

2,000 micrograms (8 puffs)

The total daily dose may be divided into 2, 3 or 4 doses per day. This product strength is not suitable for children If you use more Clenil Modulite than you should: Tell your doctor as soon as possible. Your doctor may want to check the cortisol levels in your blood and therefore, may need to take a blood sample (cortisol is a steroid hormone which occurs naturally in the body). It is important that you take your dose as stated on the pharmacist's label or as advised by your doctor. You should not increase or decrease your dose without seeking medical advice. If you forget to use Clenil Modulite: If you forget to take your Clenil Modulite, miss out your forgotten dose and take the next dose when it is due. Do not take more puffs than you were told to take. Instructions for use: It is important that you know how to use your inhaler properly. Your doctor, nurse or pharmacist will show you how to use your inhaler correctly and will check regularly that you are using your inhaler correctly. You must follow their instructions carefully, so that you know how, when and how many puffs to inhale and how often you must use your inhaler. The instructions should be on the pharmacist's label and are given in this leaflet. If you are not sure what to do or have problems inhaling then ask your doctor, nurse or pharmacist for advice. This medicine is contained in a pressurised canister in a plastic casing with a mouthpiece. There is a dose indicator on the back of the inhaler which tells you how many puffs are left:

Each time you press the canister, the dose indicator rotates by a small amount. The number of puffs remaining is displayed in intervals of 20. Take care not to drop the inhaler as this may cause the dose indicator to count down.

1

2 1-2

3 3A

3B

7

4

5-6 4C 4B 4A 1. To remove the mouthpiece cover, hold between the thumb and forefinger, squeeze gently and pull apart as shown. Check inside and outside to make sure that the mouthpiece is clean, and that there are no foreign objects.

Testing Your Inhaler: If the inhaler is new or if it has not been used for three days or more, one puff should be released into the air to make sure that it works. If you are testing your inhaler for the first time, 200 should be displayed on the dose indicator. 2. Hold the inhaler upright as shown, with your thumb on the base, below the mouthpiece. Breathe out as far as is comfortable. 3. Place the mouthpiece in your mouth between your teeth and close your lips around it but do not bite it. 4. Just after starting to breathe in through your mouth press down on the top of the inhaler to release a puff while still breathing in steadily and deeply 5. Hold your breath; take the inhaler from your mouth and your finger from the top of the inhaler. Continue holding your breath for a few seconds or as long as is comfortable. Breathe out slowly. 6. If you are to take another puff, keep the inhaler upright and wait about half a minute before repeating steps 2 to 5. 7. After use always replace the mouthpiece cover to keep out dust and fluff. Replace firmly, snap into position and check the dose indicator. Important: Do not rush steps 2, 3, 4 and 5. It is important that you start to breathe in as slowly as possible just before operating the inhaler. Practice in front of a mirror for the first few times.

Please read back of this leaflet Chiesi item

PAG. 1/2

CHIESI FARMACEUTICI S.p.A. – Parma – Italy NOT TO TAMPER THIS DOCUMENT

Artwork Owner: MS – mail: [email protected] MATERIAL TIPE: DESCRIPTION OF MATERIAL: FORMAT: DIMENSIONS mm: FONT AND min. SIZE: LAETUS CODE:

MOCK-UP FOR SUBMISSION LEAFLET MOCK-UP CLENIL MOD. 50/100/200/250 mcg D.I. UK F091 BACK 180 x 800 AFTER FOLDING: 180 x 39 Arial 8,5 pt The laetus or datamatrix code assigned in the Datamatrix Laetus code production code will be used to avoid the mix-up code is dummy is dummy

or DATAMATRIX CODE:

Black + halft 20%

COLOUR PRINT N.: 1

DIECUT

Reason of the change: New mock-up for UK submission: EU F-gas Regulation_labeling requirements Text received on 15/11/2024 From: Darr K. CHECK BY

Name:

Date:

PROOF N. /

1 2

DATE

FROM: /CHANGE FOR

28/11/2024 START ACTIVITY 02/12/2024 Drawing change from 180 doses to 200 requested by Darr on 02/12/2024

When to replace your inhaler When the indicator shows 20 doses left, you should request a new inhaler from your doctor. This will ensure you have a replacement in good time. When the '0' appears centrally in the window the medicine has run out and you should discard the inhaler. Your inhaler may feel like there are still some contents remaining but any remaining puffs may not contain enough medicine and should not be used. If you see 'mist' coming from the top of the inhaler or the sides of your mouth, Clenil will not get into your lungs as it should. Take another puff, carefully following the instructions from Step 2 onwards. People with weak hands or children may find it easier to hold the inhaler with both hands. Put the two forefingers on top of the inhaler and both thumbs on the bottom below the mouthpiece. If you find it difficult to operate the inhaler while starting to breathe in you may use the Volumatic spacer device. Ask your doctor, pharmacist or a nurse about this device. However, the Volumatic spacer device must always be used if:

  • you are an adult, elderly or an adolescent 16 years of age and older and are taking total daily doses of Clenil Modulite of 1,000 micrograms or more,
  • Clenil Modulite is used in children and adolescents 15 years of age and younger, whatever dose has been prescribed. Young children may find it difficult to use the inhaler properly and will require help. Using the inhaler with the Volumatic spacer device with a face mask may help in children under 5 years. Tell your doctor, nurse or pharmacist if you have any difficulties. Cleaning your inhaler: You should clean your inhaler once a week. When cleaning, do not remove the canister can from the actuator and do not use water or other liquids to clean your inhaler. To clean your inhaler: 1. Remove the protective cap from the mouthpiece by pulling it away from your inhaler. 2. Use a clean cotton swab to clean the small circular opening where the medicine sprays out of the canister. Gently twist the swab in a circular motion to take off any medicine. 3. Replace the mouthpiece cover. It is important that you also read the Package leaflet which is supplied with your Volumatic spacer device and that you follow the instructions on how to use the Volumatic and on how to clean it, carefully.

Possible side effects

Like all medicines, Clenil Modulite can cause side effects, although not everybody gets them. If you notice an immediate increase in wheezing, shortness of breath and cough straight after using your inhaler, stop using Clenil Modulite and use a quick-acting 'reliever' inhaler immediately. Contact your doctor straightaway. Your doctor will review your asthma and may change your treatment and may prescribe a different inhaler to treat your asthma. The following side effects have been reported. Tell your doctor as soon as possible if you suffer from any of these side effects but do not stop treatment unless told to do so. Your doctor will try to prevent these effects by prescribing Clenil Modulite in the lowest dose possible to control your asthma. Very Common (may affect more than 1 in 10 people):

  • Thrush in the mouth and throat. This is more likely if the daily dose taken is greater than 400 micrograms. Thrush can be treated with anti-fungal medicines whilst you continue to use Clenil Modulite. Brushing your teeth, or thoroughly rinsing your mouth with water immediately after each dose may help prevent thrush. Common (may affect up to 1 in 10 people):
  • Hoarse voice or a sore throat or tongue. Using a Volumatic spacer device or rinsing your mouth with water immediately after using your inhaler may help prevent this. Uncommon (may affect up to 1 in 100 people):
  • Allergic reactions including skin rashes, hives, itching or redness. Very rare (may affect up to 1 in 10,000 people):
  • Swelling of the face, eyes, lips and throat.
  • Changes to the normal production of the steroids in the body, particularly after treatment with Clenil Modulite at high doses over a long period of time.
  • Children and adolescents may grow more slowly and may need to have their height checked regularly by their doctor. This occurs particularly after treatment with Clenil Modulite at high doses over a long period of time.
  • A decrease in bone mineral density (thinning and weakening of the bones) and eye problems which include the formation of cataracts and glaucoma (increased pressure in the eye).
  • If you become unwell or develop symptoms such as loss of appetite, abdominal pain, weight loss, tiredness, nausea (feeling sick), vomiting (being sick), feeling faint, sweating and possible convulsions (fits), you should consult your doctor. This is particularly important if you have been exposed to stress such as surgery, infection, an acute attack of asthma, or other serious illness. Your doctor may carry out blood test from time to time to monitor the levels of steroids in your body. Unknown (frequency cannot be estimated from the available data):
  • Sleeping problems, depression or feeling worried, restless, nervous, over-excited or irritable. These effects are more likely to occur in children.
  • Headaches
  • Nausea (feeling sick)
  • Blurred vision If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. Reporting of side effects If you get any side effects talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the YellowCard Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Clenil Modulite

  • Keep this medicine out of the sight and reach of children.
  • Do not use Clenil Modulite after the expiry date which is stated on the carton and label. The expiry date refers to the last day of that month.
  • Do not store the inhaler above 30°C. Protect from frost and direct sunlight.
  • If the inhaler gets very cold, take the metal canister out of the plastic case and warm it in your hands for a few minutes before use. Never use anything else to warm it up.
  • Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment. Warning: The canister contains a pressurised liquid. Keep away from heat and direct sunlight, do not expose to high temperatures (above 50°C) and do not puncture or burn (incinerate), even when empty.

Contents of the pack and other information

What Clenil Modulite contains The active substance of your inhaler is beclometasone dipropionate. Each puff contains 50, 100, 200 or 250 micrograms of beclometasone dipropionate. The other ingredients are glycerol, ethanol and the propellant norflurane (HFC-134a). Clenil Modulite 50: This medicine contains fluorinated greenhouse gases. Each inhaler contains 12.130 g of norflurane (HFC-134a) corresponding to 0.017 tonne CO2 equivalent (global warming potential GWP = 1430). Clenil Modulite 100: This medicine contains fluorinated greenhouse gases. Each inhaler contains 12.130 g of norflurane (HFC-134a) corresponding to 0.017 tonne CO2 equivalent (global warming potential GWP = 1430). Clenil Modulite 200: This medicine contains fluorinated greenhouse gases. Each inhaler contains 11.950 g of norflurane (HFC-134a) corresponding to 0.017 tonne CO2 equivalent (global warming potential GWP = 1430). Clenil Modulite 250: This medicine contains fluorinated greenhouse gases. Each inhaler contains 11.780 g of norflurane (HFC-134a) corresponding to 0.017 tonne CO2 equivalent (global warming potential GWP = 1430). What Clenil Modulite looks like and content of the pack Clenil Modulite is a pressurised inhalation solution contained in an aluminum can with plastic actuator and protective cap. Each canister contains 200 puffs. Marketing Authorisation Holder and Manufacturer The Marketing Authorisation Holder of Clenil Modulite is Chiesi Limited, 333 Styal Road, Manchester, M22 5LG, United Kingdom. The manufacturer of Clenil Modulite is Chiesi Farmaceutici S.p.A., 96 via S. Leonardo, 43122 Parma, Italy or Chiesi S.A.S., 2 rue des Docteurs Alberto et Paolo Chiesi, 41260 La Chaussee Saint Victor, France.

Is this leaflet hard to see or read? Phone 0161 488 5555 for help. The leaflet was last revised in 12/2024 Volumatic is a registered trademark of the GlaxoSmithKline Group of Companies.

CP0016/15

Chiesi item

PAG. 2/2

Frequently asked questions about Clenil Modulite 100 micrograms inhaler (with Dose Indicator)

How do I take Clenil Modulite 100 micrograms inhaler (with Dose Indicator)?

Clenil Modulite 100 micrograms inhaler (with Dose Indicator) comes as inhaler containing 100mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Clenil Modulite 100 micrograms inhaler (with Dose Indicator)?

The active substance in Clenil Modulite 100 micrograms inhaler (with Dose Indicator) is beclometasone dipropionate.

Are there equivalent medicines to Clenil Modulite 100 micrograms inhaler (with Dose Indicator)?

Medicines with the same active substance, strength and form include: Clenil Modulite 100 micrograms inhaler (without Dose Indicator), Kelhale 100 micrograms per actuation pressurised inhalation solution, Soprobec 100 micrograms per actuation pressurised inhalation solution. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Clenil Modulite 100 micrograms inhaler (with Dose Indicator), as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Clenil Modulite 100 micrograms inhaler (with Dose Indicator) without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Beclometasone dipropionate (44 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Clenil Modulite is indicated for the prophylactic management of mild, moderate, or severe asthma in adults or children:

Mild asthma: Patients requiring intermittent symptomatic bronchodilator asthma medication on a regular basis

Moderate asthma: Patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone

Severe asthma: Patients with severe chronic asthma and those who are dependent on systemic corticosteroids for adequate control of symptoms

4.2. Posology and method of administration

Posology

Clenil Modulite is for inhalation use only. The Volumatic™ spacer device may be used by patients who have difficulty synchronising aerosol actuation with inspiration of breath.

The starting dose of inhaled beclometasone dipropionate should be adjusted to the severity of the disease. The dose may then be adjusted until control is achieved and then should be titrated to the lowest dose at which effective control of asthma is maintained.

Adults (including the elderly): The usual starting dose is 200 micrograms twice daily. In severe cases this may be increased to 600 to 800 micrograms daily. This may then be reduced when the patient's asthma has stabilised. The total daily dosage should be administered as two to four divided doses.

The Volumatic™ spacer device must always be used when Clenil Modulite is administered to adults and adolescents 16 years of age and older taking total daily doses of 1000 micrograms or greater.

Children: The usual starting dose is 100 micrograms twice daily. Depending on the severity of asthma, the daily dose may be increased up to 400 micrograms administered in two to four divided doses.

Clenil Modulite must always be used with the Volumatic™ spacer device when administered to children and adolescents 15 years of age and under, whatever dose has been prescribed.

Patients with hepatic or renal impairment: No dosage adjustment is needed in patients with hepatic or renal impairment.

Method of Administration

The aerosol spray is inhaled through the mouth into the lungs. The correct administration is essential for successful therapy. The patient must be instructed on how to use Clenil Modulite correctly and advised to read and follow the instructions printed on the Patient Information Leaflet carefully.

Instructions for Use

Patients should be instructed in the proper use of their inhaler (see patient information leaflet)

During inhalation, the patient should preferably sit or stand. The inhaler has been designed for use in a vertical position.

Testing the inhaler:

If the inhaler is new or has not been used for three days or more, one puff should be released into the air. It is not necessary to shake the inhaler before use because this is a solution aerosol.

Instruct the patient to remove the mouthpiece cover and check that it is clean and free from foreign objects. The patient should then be instructed to breathe out before placing the inhaler into their mouth. They should then close their lips around the mouthpiece and breathe in steadily and deeply. They must not bite the mouthpiece. After starting to breathe in through the mouth, the top of the inhaler should be pressed down. Whilst the patient is still breathing in, the patient should then remove the inhaler from their mouth and hold their breath for about 5 to 10 seconds, or as long as is comfortable, and then breathe out slowly. The patient must not breathe out into the inhaler. If another dose is required, the patient should be advised to wait 30 seconds before repeating the procedure just described. Finally, patients should breathe out slowly and replace the mouthpiece cover.

The patient should be told not to rush the procedure described. It is important that the patient breathes in as slowly as possible prior to actuation. Inform the patient that if a mist appears on inhalation, the procedure should be repeated.

There is a dose indicator on the back of the inhaler which tells you how many puffs are left, the dose indicator rotates by a small amount when a puff is delivered. The number of puffs remaining is displayed in intervals of 20.

Patients should consider getting a replacement when the indicator shows the number 20. The indicator will stop at 0 when all the recommended puffs have been used. Replace the inhaler when the indicator reads 0.

It may be helpful to advise children and patients with weak hands to hold the inhaler with two hands, by placing both forefingers on top of the inhaler and both thumbs at the bottom of the device.

Patients who find it difficult to co-ordinate actuation with inspiration of breath should be told to use a Volumatic™ spacer device to ensure proper administration of the product.

Young children may find it difficult to use the inhaler properly and will require help. Using the inhaler with the Volumatic™ spacer device with a face mask may help in children under 5 years.

Advise the patient to thoroughly rinse the mouth or gargle with water or brush the teeth immediately after using the inhaler.

The patient should be told of the importance of cleaning the inhaler at least weekly to prevent any blockage and to carefully follow the instructions on cleaning the inhaler printed on the Patient Information Leaflet. The inhaler must not be washed or put in water.

The patient should be told also to refer to the Patient Information Leaflet accompanying the VolumaticTM spacer device for the correct instructions on its use and cleaning.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Patients should be properly instructed on the use of the inhaler to ensure that the drug reaches the target areas within the lungs. Patients should also be informed that Clenil Modulite should be used on a regular basis, even when they are asymptomatic.

Clenil Modulite does not provide relief of acute asthma symptoms, which require a short-acting inhaled bronchodilator. Patients should have relief medication available.

Severe asthma requires regular medical assessment, including lung-function testing, as there is a risk of severe attacks and even death. Patients should be instructed to seek medical attention if short-acting relief bronchodilator treatment becomes less effective, or more inhalations than usual are required as this may indicate deterioration of asthma control. If this occurs, patients should be assessed and the need for increased anti-inflammatory therapy considered (eg. higher doses of inhaled corticosteroid or a course of oral corticosteroid).

Severe exacerbations of asthma must be treated in the usual way, ie. by increasing the dose of inhaled beclometasone dipropionate, giving a systemic steroid if necessary, and/or an appropriate antibiotic if there is an infection, together with β-agonist therapy.

Treatment with Clenil Modulite should not be stopped abruptly.

Systemic effects of inhaled corticosteroids may occur, particularly when prescribed at high doses for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is important that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained.

It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroids, if possible, to the lowest dose at which effective control of asthma is maintained. In addition, consideration should also be given to referring the patient to a paediatric respiratory specialist.

Prolonged treatment with high doses of inhaled corticosteroids may result in clinically significant adrenal suppression.

Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.

The transfer to Clenil Modulite of patients who have been treated with systemic steroids for long periods of time or at high doses needs special care, since recovery from possible adrenocortical suppression may take considerable time. Reduction of the dose of systemic steroid can be commenced approximately one week after initiating treatment with Clenil Modulite. The size of the reduction should correspond to the maintenance dose of systemic steroid. For patients receiving maintenance doses of 10 mg daily or less of prednisolone (or equivalent) reductions in dose of not more than 1 mg are suitable. For higher maintenance doses, larger reductions in dose may be appropriate. These oral dosage reductions should be introduced at not less than weekly intervals.

Adrenocortical function should be monitored regularly as the dose of systemic steroid is gradually reduced.

Some patients feel unwell during withdrawal of systemic steroids despite maintenance or even improvement of respiratory function. They should be encouraged to persevere with inhaled beclometasone dipropionate and to continue withdrawal of systemic steroid, unless there are objective signs of adrenal insufficiency.

Patients weaned off oral steroids whose adrenocortical function is impaired should carry a steroid warning card indicating that they may need supplementary systemic steroids during periods of stress, eg. worsening asthma attacks, chest infections, major intercurrent illness, surgery, trauma, etc.

Replacement of systemic steroid treatment with inhaled therapy sometimes unmasks allergies such as allergic rhinitis or eczema previously controlled by the systemic drug. These allergies should be symptomatically treated with antihistamine and/or topical preparations, including topical steroids.

As with all inhaled corticosteroids, special care is necessary in patients with active or quiescent pulmonary tuberculosis.

Visual disturbance

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

Clenil Modulite contains a small amount of glycerol and ethanol (alcohol), approximately 9 mg per actuation, which is equivalent to 0,44 mg/kg per dose of four actuations in adults and 0,76 mg/kg per dose of two actuations in children. The small amount of alcohol and glycerol in this medicine will not have any noticeable effects.

4.5. Interaction with other medicinal products and other forms of interaction

Clenil Modulite contains a small amount of ethanol. There is a theoretical potential for interaction in particularly sensitive patients taking disulfiram or metronidazole.

Beclometasone is less dependent on CYP3A metabolism than some other corticosteroids, and in general interactions are unlikely; however the possibility of systemic effects with concomitant use of strong CYP3A inhibitors (e.g. ritonavir, cobicistat) cannot be excluded, and therefore caution and appropriate monitoring is advised with the use of such agents.

4.6. Fertility, pregnancy and lactation

There is no experience of the use of this product in pregnancy and lactation in humans. It should not be used in pregnancy or lactation unless the expected benefits to the mother are thought to outweigh any potential risks to the fetus or neonate.

There is inadequate evidence of safety of beclometasone dipropionate in human pregnancy. Administration of corticosteroids to pregnant animals can cause abnormalities of fetal development including cleft palate and intra-uterine growth retardation. There may therefore, be a risk of such effects in the human fetus. It should be noted, however, that the fetal changes in animals occur after relatively high systemic exposure. Beclometasone dipropionate is delivered directly to the lungs by the inhaled route and so avoids the high level of exposure that occurs when corticosteroids are given by systemic routes.

No specific studies examining the transfer of beclometasone dipropionate into the milk of lactating animals have been performed. It is reasonable to assume that beclometasone dipropionate is secreted in milk, but at the dosages used for direct inhalation there is low potential for significant levels in breast milk.

There is no experience with or evidence of safety of propellant HFA-134a in human pregnancy or lactation. However, studies of the effect of HFA-134a on reproductive function and embryofetal development in animals have revealed no clinically relevant adverse effects.

4.7. Effects on ability to drive and use machines

None reported

4.8. Undesirable effects

Adverse events are listed below by system class and frequency. Frequencies are defined as: very common (>1/10), common (>1/100 and <1/10), uncommon (>1/1,000 and <1/100), rare (>1/10,000 and <1/1,000), very rare (<1/10,000), unknown (frequency cannot be estimated from the available data).

System organ Class

Adverse Reaction

Frequency

Infections and Infestations

Oral candidiasis (of the mouth and throat)

Very Common

Immune System Disorders

Hypersensitivity reaction with the following manifestations:

Rash, urticaria, pruritus, erythema

Uncommon

Oedema of the eyes, face, lips and throat

Very Rare

Endocrine Disorders

Adrenal suppression*, growth retardation* (in children and adolescents), bone density decreased*

Very Rare

Psychiatric Disorders (see section 4.4 Special warnings and precautions for use)

Psychomotor hyperactivity, sleep disorders, anxiety, depression, aggression, behavioural disorders (predominantly in children)

Unknown

Nervous System Disorders

Headache

Unknown

Eye Disorders

Cataract*, glaucoma*

Very Rare

Vision, blurred (see also section 4.4)

Unknown

Respiratory, Thoracic and Mediastinal Disorders

Hoarseness, throat irritation

Common

Paradoxial bronchospasm, wheezing, dyspnoea, cough

Very Rare

Gastrointestinal Disorders

Nausea

Unknown

*Systemic reactions are a possible response to inhaled corticosteroids, especially when a high dose is prescribed for a prolonged time (see section 4.4 Special warnings and precautions for use).

As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing, shortness of breath and cough after dosing. This should be treated immediately with a fast-acting inhaled bronchodilator. Clenil Modulite should be discontinued immediately, the patient assessed and, if necessary, alternative therapy instituted.

Candidiasis of the mouth and throat occurs in some patients, the incidence increasing with doses greater than 400 micrograms beclometasone dipropionate per day. Patients with high blood levels of Candida precipitins, indicating a previous infection, are most likely to develop this complication. Patients may find it helpful to rinse their mouth thoroughly with water after inhalation. Symptomatic oral candidiasis can be treated with topical antifungal therapy while continuing with Clenil Modulite.

Hoarseness or throat irritation may occur in some patients. These patients should be advised to rinse the mouth out with water immediately after inhalation. Use of the Volumatic™ spacer device may be considered.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Acute: Inhalation of doses in excess of those recommended may lead to temporary suppression of adrenal function. This does not require emergency action. In these patients treatment should be continued at a dose sufficient to control asthma; adrenal function recovers in a few days and can be verified by measuring plasma cortisol.

Chronic: Use of inhaled beclometasone dipropionate in daily doses in excess of 1,500 micrograms over prolonged periods may lead to adrenal suppression. Monitoring of adrenal reserve may be indicated. Treatment should be continued at a dose sufficient to control asthma.

💬 Ask about this leaflet

Ask anything about Clenil Modulite 100 micrograms inhaler (with Dose Indicator). The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →